30
Participants
Start Date
August 24, 2021
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2028
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions
Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
New York Medical College, Valhalla
AdventHealth Orlando, Orlando
Johns Hopkins All Children's Hospital, St. Petersburg
Nationwide Children's Hospital, Columbus
Cleveland Clinic Lerner College of Medicine, Cleveland
Medical College of Wisconsin, Milwaukee
Ann & Robert H. Lurie Children's Hospital, Chicago
Washington University, St. Louis, St Louis
Children's Hospital Colorado, Aurora
University of Utah, Salt Lake City
Phoenix Children's Hospital, Phoenix
Children's Hospital Los Angeles, Los Angeles
Fred Hutchinson Cancer Center, Seattle
Nationwide Children's Hospital
OTHER
Seattle Children's Hospital
OTHER
Michael Pulsipher
OTHER